Przejdź do zawartości
Merck

ADCK1 activates the β-catenin/TCF signaling pathway to promote the growth and migration of colon cancer cells.

Cell death & disease (2021-04-08)
Yong Ji, Yiqian Liu, Changchun Sun, Lijiang Yu, Zhao Wang, Xu Du, Wu Yang, Chenggong Zhang, Chunmu Tao, Jianjiang Wang, Xi Yang, Sun Di, Yufeng Huang
ABSTRAKT

As a result of mutations in the upstream components of the Wnt/β-catenin signaling pathway, this cascade is abnormally activated in colon cancer. Hence, identifying the activation mechanism of this pathway is an urgent need for the treatment of colon cancer. Here, we found an increase in ADCK1 (AarF domain-containing kinase 1) expression in clinical specimens of colon cancer and animal models. Upregulation of ADCK1 expression promoted the colony formation and infiltration of cancer cells. Downregulation of ADCK1 expression inhibited the colony formation and infiltration of cancer cells, in vivo tumorigenesis, migration, and organoid formation. Molecular mechanistic studies demonstrated that ADCK1 interacted with TCF4 (T-cell factor 4) to activate the β-catenin/TCF signaling pathway. In conclusion, our research revealed the functions of ADCK1 in the development of colon cancer and provided potential therapeutic targets.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Anti-ADCK1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution